MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

A

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

Search

TransMedics Group Inc

Open

SectorHealthcare

135.57 0.68

Overview

Share price change

24h

Current

Min

131.5

Max

137.81

Key metrics

By Trading Economics

Income

-11M

24M

Sales

-14M

144M

P/E

Sector Avg

56.445

89.037

Profit margin

16.909

Employees

728

EBITDA

-13M

33M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+6.7% upside

Dividends

By Dow Jones

Next Earnings

26 Feb 2026

Market Stats

By TradingEconomics

Market Cap

384M

4.9B

Previous open

134.89

Previous close

135.57

News Sentiment

By Acuity

50%

50%

177 / 360 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

TransMedics Group Inc Chart

Past performance is not a reliable indicator of future results.

Related News

4 Aug 2025, 19:15 UTC

Major Market Movers

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

Peer Comparison

Price change

TransMedics Group Inc Forecast

Price Target

By TipRanks

6.7% upside

12 Months Forecast

Average 151.44 USD  6.7%

High 170 USD

Low 135 USD

Based on 11 Wall Street analysts offering 12 month price targets forTransMedics Group Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

9

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

92.43 / 94.18Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

177 / 360 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat